The Global Health Body Issues Concern Over Critical Scarcity of Weight-Loss Jabs

Less than 10% of individuals eligible to benefit from weight-loss injections like Wegovy can access them, states the WHO as it releases its initial advice on the drugs.

With over a billion people worldwide currently obese, it is advocating for increased and just access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.

"The new guidelines affirms that excess weight is a chronic disease that can be addressed with thorough and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are major hurdles to widespread availability to the treatments that can assist patients in reducing substantial body mass, explains the body.

Weight-Loss Drug Shortage

Even under the present best projected outlook, the manufacturing of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, according to the health organization.

The guideline calls on countries and companies to widen access, through approaches including licensing agreements.

A patent on semaglutide – the core ingredient of a leading brand – is due to expire in a number of countries in 2026.

How Obesity Jabs Function

These medications replicate a body's own hormone to slow digestion, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.

People usually start to lose weight within a few weeks of beginning the regular doses.

Evidence suggests users may see weight return a year later of stopping the treatment, when their normal hunger come back.

Being overweight or obese increases your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific malignancies.

Obesity concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.